• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对阿西替尼耐药的费城染色体阳性细胞的表征。

Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells.

作者信息

Okabe Seiichi, Moriyama Mitsuru, Gotoh Akihiko

机构信息

Department of Hematology, Tokyo Medical University, Tokyo, Japan.

出版信息

World J Oncol. 2024 Apr;15(2):319-324. doi: 10.14740/wjon1818. Epub 2024 Mar 21.

DOI:10.14740/wjon1818
PMID:38545482
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10965256/
Abstract

BACKGROUND

Asciminib is approved for treating patients with chronic-phase chronic myeloid leukemia who were previously treated with two or more tyrosine kinase inhibitors or those with mutation. However, the mechanisms underlying asciminib resistance remain unclear.

METHODS

In this study, we established a new asciminib-resistant cell line. We examined gene mutation analysis and the effects of conventional chronic myelogenous leukemia inhibitors.

RESULTS

Direct sequencing revealed and mutations in asciminib-resistant cells. Ponatinib and omacetaxine were effective against asciminib-resistant cells.

CONCLUSIONS

and mutations are extremely resistant to asciminib. Ponatinib and omacetaxine show potential for treating asciminib-resistant chronic myeloid leukemia.

摘要

背景

阿伐替尼已被批准用于治疗先前接受过两种或更多酪氨酸激酶抑制剂治疗的慢性期慢性髓性白血病患者或有特定突变的患者。然而，阿伐替尼耐药的潜在机制仍不清楚。

方法

在本研究中，我们建立了一种新的阿伐替尼耐药细胞系。我们进行了基因突变分析以及传统慢性髓性白血病抑制剂的效果研究。

结果

直接测序显示阿伐替尼耐药细胞中有特定突变。普纳替尼和奥马西他辛对阿伐替尼耐药细胞有效。

结论

特定突变对阿伐替尼具有极高耐药性。普纳替尼和奥马西他辛在治疗阿伐替尼耐药的慢性髓性白血病方面显示出潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c814/10965256/a28c7af44a1a/wjon-15-319-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c814/10965256/b946724c7e4e/wjon-15-319-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c814/10965256/a28c7af44a1a/wjon-15-319-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c814/10965256/b946724c7e4e/wjon-15-319-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c814/10965256/a28c7af44a1a/wjon-15-319-g002.jpg

相似文献

1
Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells.对阿西替尼耐药的费城染色体阳性细胞的表征。
World J Oncol. 2024 Apr;15(2):319-324. doi: 10.14740/wjon1818. Epub 2024 Mar 21.
2
Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing -compound mutations.阿斯科利尼布和波纳替尼对表达复合突变的慢性粒细胞白血病细胞具有协同抗肿瘤作用。
Am J Cancer Res. 2021 Sep 15;11(9):4470-4484. eCollection 2021.
3
Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.阿斯科利尼布（Scemblix）：用于慢性期慢性髓性白血病伴或不伴T315I突变的三线治疗选择。
Am J Health Syst Pharm. 2023 Jan 5;80(2):36-43. doi: 10.1093/ajhp/zxac286.
4
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.阿西替尼在 ABL 激酶抑制剂失败后的慢性髓性白血病中的应用。
N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.
5
Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.ASCIMIB 在慢性期费城染色体阳性慢性髓性白血病中的暴露-疗效分析。
Clin Pharmacol Ther. 2022 Nov;112(5):1040-1050. doi: 10.1002/cpt.2699. Epub 2022 Jul 31.
6
Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells.阿西替尼和维生素 K2 对阿博利珠单抗耐药慢性髓性白血病细胞的影响。
BMC Cancer. 2023 Sep 5;23(1):827. doi: 10.1186/s12885-023-11304-4.
7
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1 and BCR-ABL1.克唑替尼作为一种ABL1抑制剂，兼具ATP结合和变构抑制作用，对天然BCR-ABL1及其耐药和复合突变体BCR-ABL1均有活性。
Ann Hematol. 2021 Aug;100(8):2023-2029. doi: 10.1007/s00277-020-04357-z. Epub 2021 Jun 10.
8
Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.阿西替尼治疗的费城染色体阳性慢性髓性白血病慢性和急变期患者的 ASCIMIB 群体药代动力学。
Clin Pharmacokinet. 2022 Oct;61(10):1393-1403. doi: 10.1007/s40262-022-01148-9. Epub 2022 Jun 28.
9
Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.阿伐替尼治疗费城染色体阳性慢性髓性白血病：聚焦患者选择与治疗结果
Cancer Manag Res. 2023 Aug 23;15:873-891. doi: 10.2147/CMAR.S353374. eCollection 2023.
10
The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.EMA 评估 ASCIMINIB 治疗既往至少接受过两种酪氨酸激酶抑制剂治疗的费城染色体阳性慢性期成人慢性髓性白血病患者
Oncologist. 2023 Jul 5;28(7):628-632. doi: 10.1093/oncolo/oyad119.

引用本文的文献

1
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent.慢性髓性白血病的不同体外模型表现出不同特征：生物复制品并非生物学等效。
Cell Biol Int. 2025 May;49(5):570-586. doi: 10.1002/cbin.70007. Epub 2025 Mar 1.
2
Correspondence to: "Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations", Curik N et al. Leukemia. 2024; 38: 1415-1418.致信：“在伴有复合突变的慢性髓性白血病急变期临床前模型中泊那替尼与阿西替尼的联合治疗”，Curik N等人。《白血病》。2024年；38: 1415 - 1418。
Leukemia. 2025 Mar;39(3):775-778. doi: 10.1038/s41375-025-02521-w. Epub 2025 Feb 6.

本文引用的文献

1
Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.阿伐替尼治疗费城染色体阳性慢性髓性白血病：聚焦患者选择与治疗结果
Cancer Manag Res. 2023 Aug 23;15:873-891. doi: 10.2147/CMAR.S353374. eCollection 2023.
2
A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation.一项关于慢性期慢性髓性白血病患者三线治疗或T315I突变的治疗、疾病模式及临床结局的多中心回顾性病历审查研究。
Cancers (Basel). 2023 Aug 18;15(16):4161. doi: 10.3390/cancers15164161.
3
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
阿西替尼对比博舒替尼治疗至少两种酪氨酸激酶抑制剂治疗后的慢性期慢性髓性白血病：ASCEMBL 的长期随访。
Leukemia. 2023 Mar;37(3):617-626. doi: 10.1038/s41375-023-01829-9. Epub 2023 Jan 30.
4
Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.阿西替尼：治疗失败的慢性期 CML 的新治疗选择。
Blood. 2022 Jun 16;139(24):3474-3479. doi: 10.1182/blood.2021014689.
5
Asciminib: First Approval.阿伐替尼：首次获批。
Drugs. 2022 Feb;82(2):219-226. doi: 10.1007/s40265-021-01662-3.
6
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.一项 3 期、开放标签、随机研究，评估了 STAMP 抑制剂 ASCiminib 与博舒替尼（一种二代 TKI）在 2 种或更多种 TKI 治疗后 CML 患者中的疗效。
Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984.
7
Role of the ABL tyrosine kinases in the epithelial-mesenchymal transition and the metastatic cascade.ABL 酪氨酸激酶在上皮-间质转化和转移级联中的作用。
Cell Commun Signal. 2021 May 22;19(1):59. doi: 10.1186/s12964-021-00739-6.
8
Third-line therapy for chronic myeloid leukemia: current status and future directions.慢性髓性白血病的三线治疗：现状与未来方向。
J Hematol Oncol. 2021 Mar 18;14(1):44. doi: 10.1186/s13045-021-01055-9.
9
A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected.奥马西他辛综述：一种重获新生的慢性髓性白血病治疗药物
Oncol Ther. 2018 Jun;6(1):9-20. doi: 10.1007/s40487-018-0058-6. Epub 2018 Mar 15.
10
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.慢性髓性白血病：诊断、治疗和监测的 2020 更新。
Am J Hematol. 2020 Jun;95(6):691-709. doi: 10.1002/ajh.25792. Epub 2020 Apr 10.